Hypertension and hyperlipidaemia are major risk factors for the development of
atherosclerosis. Calcium channel blockers (CCBs) have been used for decades and have …

Therapies that lower blood pressure or lipid levels slow the progression of atherosclerosis,
and reduce morbidity and mortality in patients with hypertension or atherosclerotic disease …

Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …

Treatment of atherosclerosis has focused mainly on decreasing low-density lipoprotein
cholesterol (LDL-C). However, recent coronary angiography trials have revealed that …

BACKGROUND: We hypothesized that atorvastatin combined with amlodipine has additive
beneficial vascular and metabolic effects that are superior to monotherapy in patients with …

Molecular differences among the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) give rise to some important differences in their properties …

Background Combining statins with antihypertensive therapy has been demonstrated to
provide an early reduction in cardiovascular events. This nested substudy of the AVALON …

Calcium channel blockers and HMG-CoA reductase inhibitors are widely used for the
management of hypertension and dyslipidemia, respectively. The use of these agents in the …

Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …

Atorvastatin (Lipitor®) is an HMG-CoA reductase inhibitor with well documented lipid-
lowering effects. It has recently been evaluated for the primary prevention of major …